Device: mri (DrugBank: -)
3 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
70 | Spinal stenosis | 1 |
85 | Idiopathic interstitial pneumonia | 1 |
278 | Huge lymphatic malformation with cervicofacial lesion | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02932020 (ClinicalTrials.gov) | October 2016 | 4/10/2016 | AlloGen-LI Treatment of Spinal Stenosis | Pilot Study Investigating the Utility of Epidural AlloGen-LI Injection for Treatment of Spinal Stenosis Symptoms | Low Back Pain | Drug: AlloGen-LI;Drug: depomedrol;Device: MRI;Drug: 0.5% marcaine | University of Southern California | Vivex Biomedical, Inc. | Withdrawn | 18 Years | N/A | All | 0 | N/A | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02478268 (ClinicalTrials.gov) | May 2015 | 16/6/2015 | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129-Xenon gas;Device: MRI | Bastiaan Driehuys | University of Wisconsin, Madison;National Heart, Lung, and Blood Institute (NHLBI) | Completed | 18 Years | N/A | All | 64 | Phase 1 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03243019 (ClinicalTrials.gov) | June 25, 2018 | 1/8/2017 | Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis | Lymphatic Malformation;Pediatric | Drug: rapamycin;Device: MRI;Biological: Rapamycin dosage | University Hospital, Lille | Ministry of Health, France | Recruiting | 1 Year | 18 Years | All | 28 | Phase 2 | France |